Medtronic, Inc. (NYSE:MDT), today announced approval by the U.S. Food and Drug Administration (FDA) of its new generation multi-exchange Zipper Stent Delivery Platform. This important technological advance offers interventional cardiologists the benefits without many of the limitations of current delivery platforms, which are known as over the wire and rapid exchange or single operator exchange systems.
The company now has FDA and European Union approvals for its Stent Delivery Platform and Stormer Balloon Dilitation Catheter with Zipper technology. Initial launch of the stent delivery system with Zipper Technology is slated for December in the United States, with a global launch of both products to follow shortly thereafter.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!